Merck's Keytruda fails triple negative breast cancer pivotal study
Months after the FDA sanctioned the approval of Roche’s runner up checkpoint inhibitor Tecentriq in combination with Celgene’s Abraxane for treatment naive patients with triple negative breast cancer, Merck’s keynote PD-1 Keytruda has stumbled in a late-stage trial as the second or third line of defense against the rare, aggressive form of cancer.
Patients in the 622-patient trial were either given the blockbuster treatment or chemotherapy. The main goal of the study — overall survival — was not met, Merck said, adding that details will be disclosed at a later date.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.